Sirolimus/Tanespimycin/Paclitaxel

西罗莫司/17-烯丙氨基格尔德霉素/紫杉醇

Report date: 2026/03/04 20:01:44

Base Information

Drug NameSirolimus/Tanespimycin/Paclitaxel
Drug Alias NameTriolimus
ClassificationSmall moleculesSmall molecules > Molecular Glue
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitorsHeat shock protein HSP90 inhibitors +[4] 
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2Heat shock protein HSP90 +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes SirolimusTanespimycinPaclitaxel
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCo-D Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A